Cargando…

Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis

Concentration-QTc modeling was applied to pretomanid, a new nitroimidazooxazine antituberculosis drug. Data came from eight phase 2 and phase 3 studies. Besides pretomanid alone, various combinations with bedaquiline, linezolid, moxifloxacin, and pyrazinamide were considered; special attention was g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hanbin, Salinger, David H., Everitt, Daniel, Li, Mengchun, Del Parigi, Angelo, Mendel, Carl, Nedelman, Jerry R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2019
Materias:	Clinical Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6761551/ https://www.ncbi.nlm.nih.gov/pubmed/31358590 http://dx.doi.org/10.1128/AAC.00445-19

Ejemplares similares

An Exposure-Response Perspective on the Clinical Dose of Pretomanid
por: Nedelman, Jerry R., et al.
Publicado: (2020)

Population Pharmacokinetics of the Antituberculosis Agent Pretomanid
por: Salinger, David H., et al.
Publicado: (2019)

Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers
por: Li, Mengchun, et al.
Publicado: (2020)

Daily Dosing for Bedaquiline in Patients with Tuberculosis
por: Salinger, David H., et al.
Publicado: (2019)

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
por: Diacon, Andreas H., et al.
Publicado: (2020)

Male reproductive hormones in patients treated with pretomanid
por: Boekelheide, K., et al.
Publicado: (2022)

Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis
por: Xu, Jian, et al.
Publicado: (2019)

Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
por: Li, Si-Yang, et al.
Publicado: (2017)

Bedaquiline, pretomanid and linezolid for treatment of extensively drug resistant, intolerant or non-responsive multidrug resistant pulmonary tuberculosis
por: Conradie, Francesca, et al.
Publicado: (2020)

Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects
por: Bruinenberg, Paul, et al.
Publicado: (2022)

Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
por: Li, Si-Yang, et al.
Publicado: (2023)

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
por: Ali, Ali Mohamed, et al.
Publicado: (2023)

Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
por: Oelofse, S., et al.
Publicado: (2021)

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
por: Zou, Yuanxi, et al.
Publicado: (2022)

Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial
por: Singleton, Matthew J., et al.
Publicado: (2020)

Pretomanid for tuberculosis treatment: an update for clinical purposes
por: Occhineri, Sara, et al.
Publicado: (2022)

A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
por: Tweed, C. D., et al.
Publicado: (2021)

Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid
por: Timm, Juliano, et al.
Publicado: (2023)

Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
por: Tweed, Conor D, et al.
Publicado: (2019)

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project
por: Goswami, Neela, et al.
Publicado: (2021)

Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis
por: Olliaro, Piero L., et al.
Publicado: (2017)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines
por: Gomez, Gabriela Beatriz, et al.
Publicado: (2021)

Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
por: Bateson, Anna, et al.
Publicado: (2022)

Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
por: Osawa, Mayu, et al.
Publicado: (2018)

Delamanid or pretomanid? A Solomonic judgement!
por: Mudde, Saskia E., et al.
Publicado: (2022)

Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid
por: Gómez-González, Paula J., et al.
Publicado: (2021)

QT prolongation with methadone
por: Dhamija, Radhika, et al.
Publicado: (2008)

Pretomanid dose selection for pulmonary tuberculosis: An application of multi‐objective optimization to dosage regimen design
por: Lyons, Michael A.
Publicado: (2021)

Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life
por: Somaini, Lorenzo, et al.
Publicado: (2021)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from Mycobacterium tuberculosis in vitro
por: Hu, Minghao, et al.
Publicado: (2020)

QT prolongation predicts short-term mortality independent of comorbidity
por: Gibbs, Charlotte, et al.
Publicado: (2019)

Antipsychotic Medication and QT Prolongation
por: Chohan, Paramdip Singh, et al.
Publicado: (2015)

QT Prolongation in Cancer Patients
por: Kim, Peter, et al.
Publicado: (2021)

Elevated XIAP expression alone does not confer chemoresistance
por: Seeger, J M, et al.
Publicado: (2010)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects
por: Gupta, Vipul K., et al.
Publicado: (2021)

Prolonged Remission of Psoriasis with Azathioprine Pulse Therapy
por: Gupta, Ramji
Publicado: (2015)

Beyond a prolonged QT interval
por: Bitar, Zouheir Ibrahim, et al.
Publicado: (2013)

QT Prolongation due to Graves' Disease
por: Kulairi, Zain, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_02c31ajdpn0jeig4qm5abj36q6